COPERIMOplus is funded by Fraunhofer Gesellschaft. Usually, Fraunhofer has a very limited internal funding programme, but in the course of the COVID-19 pandemic, the board of directors started a competitive funding effort at much bigger scale. The COPERIMOplus consortium was successful with the proposal of generating personalized risk models for patients. Departments and groups from 6 Fraunhofer Institutes contribute to the overall workflow underlying COPERIMOplus; this workflow is shown below.